Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Sacituzumab Govitecan vs Pembrolizumab in PD-L1 high NSCLC
NCT05609968Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of sacituzumab govitecan in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Feb 2023; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05609968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609968.